McGeorge Anne
SEC Form 4 insider trading activity
McGeorge Anne has filed 3 SEC Form 4 filings (10 transaction rows) across 2 companies, including DNTH, TOI, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 11, 2026.
On the most recent filing, McGeorge Anne is listed as Director at Dianthus Therapeutics, Inc. Inside the rolling window, McGeorge Anne reported no open-market purchases and 1 open-market sale totaling $845K in DNTH.
Companies traded
Other insiders at DNTH
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$845K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has McGeorge Anne made?
McGeorge Anne has filed 3 SEC Form 4 filings (10 transaction rows) across 2 companies, including DNTH, TOI since 2025.
Which companies does McGeorge Anne trade?
McGeorge Anne has filed SEC Form 4 disclosures for 2 companies, including DNTH, TOI.
When was McGeorge Anne's most recent SEC Form 4 filing?
McGeorge Anne's most recent SEC Form 4 filing on Tracefour is dated Aug 11, 2026.
What is McGeorge Anne's total buy and sell value in the current window?
Inside the rolling retention window, McGeorge Anne bought $0 and sold $845K based on SEC Form 4 filings.
What was McGeorge Anne's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,750 DNTH shares on 2026-08-10, worth $845K, per SEC Form 4 filings.